Biomira documents NDA for novel inhibitor of hypoxia-inducible factor-1 alpha Biomira Inc.

Food and Medication Administration for PX-478. PX-478 offers been proven in preclinical research to inhibit hypoxia-inducible element -1 alpha, a protein that handles the transcription of several genes whose items are essential for tumor development and survival. In these preclinical studies, PX-478 has created significant tumor regression and development delay in multiple types of human cancers, including cancers of the lung, breasts, prostate, colon, kidney, ovary and pancreas. HIF-1 alpha takes on a critical part in the response of tumor cells to low oxygen, a predicament observed in tumors where existing arteries are insufficient to provide needed oxygen, stated Dr.Seriously: This is the mindset of contemporary medicine: Pump people filled with drugs, chasing unwanted effects with one chemical substance after another until people either die or run out of insurance insurance coverage, at which point none of it really matters anymore. From a Big Pharma advertising perspective, the best thing about pharmaceuticals is precisely the known fact they have side effects that induce long-term repeat business. And psychiatric drugs, as it happens, are particularly good at bringing patients back again to a healthcare facility with yet more serious health problems. Sources for this story include:.

Alzheimer’s Drugs Double Death Risk Anti-psychotic drugs commonly utilized to treat Alzheimer’s disease may double a patient’s potential for dying within a few years, suggests a new study that adds to worries known about such medicines already.